Stock of the Day

July 9, 2019

Krystal Biotech (KRYS)

$359.36
+$7.90 (+2.2%)
Market Cap: $10.40B

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Today's Trend

Krystal Biotech, Inc. (NASDAQ: KRYS) shares have decreased as investors focused on a modest revenue shortfall despite solid earnings growth and encouraging progress for VYJUVEK and the company’s pipeline.

  • Adjusted earnings exceeded expectations: Krystal reported diluted EPS of $1.79, above the $1.70 consensus estimate and up from $1.29 a year earlier. Net income increased to $54.8 million from $38.3 million. Krystal Biotech Q2 earnings report
  • VYJUVEK demand remained strong: Second-quarter product revenue rose 24% year over year to $119.2 million, supported by more than 730 reimbursement approvals and over 640 prescribers. The company is also on track to launch VYJUVEK in Spain and Italy before year-end. Krystal Biotech second-quarter results
  • Pipeline catalysts are approaching: Krystal expects multiple clinical readouts in the second half of 2026, including fourth-quarter data for KB803 in corneal abrasions. It ended the quarter with approximately $1.1 billion in cash and investments, supporting continued development.
  • HC Wainwright raised its earnings forecasts for 2026, 2027 and 2028 and maintained a Buy rating with a $361 price target, citing improved longer-term earnings potential. HC Wainwright estimates
  • Revenue narrowly missed expectations: Quarterly revenue of $119.2 million was below the approximately $120.9 million consensus forecast. That miss appears to have outweighed the EPS beat in the initial market reaction. Krystal shares slide after earnings
  • Spending and execution risks remain: 2026 non-GAAP R&D and SG&A expenses are expected to total $175 million-$195 million. European pricing and reimbursement negotiations could also delay revenue growth in Germany and France.
← Previous Stock of the DayNext Stock of the Day →